{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:20:23Z","timestamp":1784035223299,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The comparative efficacy of ceftaroline and ceftobiprole against standard of care for Staphylococcus aureus infections, including methicillin-resistant S. aureus remains uncertain. Thus, we conducted a systematic review and Bayesian meta-analysis to assess the efficacy and safety of ceftaroline and ceftobiprole monotherapy for non-urinary S. aureus infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We registered the protocol in PROSPERO. We searched PubMed, Embase, Scopus, and Web of Science. We included randomized controlled trials and comparative non-randomized studies reporting adjusted estimates, enrolling patients with non-urinary S. aureus infections. The primary analysis assessed clinical cure in randomized trials using a Bayesian random-effects model with a vague prior. For ceftaroline, we additionally conducted an exploratory analysis using an observationally informed prior derived from non-randomized studies with variance inflation. Risk of bias was assessed with RoB 2 and ROBINS-I and certainty of evidence with GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen studies met inclusion criteria [11 ceftaroline (1030 subjects); 5 ceftobiprole (1265 subjects)]. In the primary analysis, the pooled odds ratio for clinical cure was 1.38 (95% CrI 0.81\u20132.44) for ceftaroline and 0.99 (95% CrI 0.59\u20131.62) for ceftobiprole. The exploratory ceftaroline analysis using an observationally informed prior yielded an odds ratio of 1.45 (95% CrI 0.91\u20132.38). Adverse events and serious adverse events were similar between groups. Certainty of evidence was low for ceftaroline and moderate for ceftobiprole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence does not demonstrate superiority of ceftaroline or ceftobiprole over standard-of-care therapy for clinical cure in non-urinary S. aureus infections. Estimates remain imprecise and are largely driven by registrational trials and subgroup data. These findings support cautious, indication-specific interpretation rather than routine preference of these agents over established therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag244","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:00:35Z","timestamp":1784034035000},"source":"Crossref","is-referenced-by-count":0,"title":["Ceftaroline and ceftobiprole monotherapy for the treatment of\n                    <i>Staphylococcus aureus<\/i>\n                    infections: a systematic review and Bayesian meta-analysis"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-9584","authenticated-orcid":false,"given":"Emanuele","family":"Rando","sequence":"first","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Instituto de Biomedicina de Sevilla\/CSIC , Seville ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Magrini","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7267-8068","authenticated-orcid":false,"given":"Flavio","family":"Sangiorgi","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Salvati","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Catania","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1591-5723","authenticated-orcid":false,"given":"Marta","family":"Chiuchiarelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Matteini","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Fantoni","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-527X","authenticated-orcid":false,"given":"Luis Eduardo","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Instituto de Biomedicina de Sevilla\/CSIC , Seville ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-9001","authenticated-orcid":false,"given":"Jes\u00fas","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Instituto de Biomedicina de Sevilla\/CSIC , Seville ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9468-5458","authenticated-orcid":false,"given":"Rita","family":"Murri","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026071409002483300_dkag244-B1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review","volume":"334","author":"Tong","year":"2025","journal-title":"JAMA"},{"key":"2026071409002483300_dkag244-B2","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1093\/cid\/ciaa994","article-title":"Combination therapy for Staphylococcus aureus bacteremia: hopes dashed again","volume":"72","author":"Tong","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026071409002483300_dkag244-B3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"2026071409002483300_dkag244-B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2023.2299377","article-title":"Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future","volume":"23","author":"Bavaro","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2026071409002483300_dkag244-B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026071409002483300_dkag244-B6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"2026071409002483300_dkag244-B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.36230","article-title":"Treatment effects in randomized and nonrandomized studies of pharmacological interventions: a meta-analysis","volume":"7","author":"Salcher-Konrad","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026071409002483300_dkag244-B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106763","article-title":"Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria","volume":"61","author":"Jean","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026071409002483300_dkag244-B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IPC.0000000000000372","article-title":"Ceftaroline fosamil for treatment of methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia and health care\u2013associated pneumonia: a 5-year matched case-control evaluation of epidemiology and outcomes","volume":"24","author":"Arshad","year":"2016","journal-title":"Infect Dis Clin Pract"},{"key":"2026071409002483300_dkag244-B10","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2026071409002483300_dkag244-B12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jgar.2018.01.001","article-title":"DISC: describing infections of the spine treated with ceftaroline","volume":"13","author":"Watkins","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2026071409002483300_dkag244-B13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/jac\/dkaf009","article-title":"Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study","volume":"80","author":"Bitterman","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B14","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071409002483300_dkag244-B15","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B16","doi-asserted-by":"publisher","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B17","doi-asserted-by":"publisher","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B18","doi-asserted-by":"publisher","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B19","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026071409002483300_dkag244-B20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071409002483300_dkag244-B21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026071409002483300_dkag244-B22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2026071409002483300_dkag244-B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026071409002483300_dkag244-B24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijantimicag.2019.06.025","article-title":"Off-label use of ceftaroline fosamil: a systematic review","volume":"54","author":"Pani","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026071409002483300_dkag244-B25","doi-asserted-by":"publisher","first-page":"230117","DOI":"10.1183\/16000617.0117-2023","article-title":"Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"32","author":"Torres","year":"2023","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"key":"2026071409002483300_dkag244-B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116263","article-title":"Ceftobiprole mono-therapy versus combination or non-combination regimen of standard antibiotics for the treatment of complicated infections: a systematic review and meta-analysis","volume":"109","author":"Jame","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026071409002483300_dkag244-B27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag244\/68770870\/dkag244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag244\/68770870\/dkag244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:00:36Z","timestamp":1784034036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag244\/8733922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag244","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dkag244"}}